HIV Citations List: February 2024

Literature Citations

1. Small Molecule Inhibitors of Transcriptional Cyclin-Dependent Kinases Impose HIV-1 Latency, Presenting "Block and Lock" Treatment Strategies. Horvath, R.M., Z.L. Brumme, and I. Sadowski. Antimicrobial Agents and Chemotherapy, 2024. 68(3): e0107223. PMID[38319085]. PMCID[PMC10923280].
[PubMed]. HIV_02_2024.

2. Synthesis and anti-HIV Activities of Phorbol Derivatives. Huang, X., C. Tang, X. Huang, Y. Yang, Q. Li, M. Ma, L. Zhao, L. Yang, Y. Cui, Z. Zhang, Y. Zheng, and J. Zhang. Chinese Journal of Natural Medicines, 2024. 22(2): p. 146-160. PMID[38342567].
[PubMed]. HIV_02_2024.

3. Synthesis, anti-HIV and Cytotoxicity Evaluation of Chiral 2,5-Disubstituted 1,3,4-thiadiazole Derivatives Bearing the Sulfonamide Scaffold. Israr, A., S. Hameed, and N.A. Al-Masoudi. Zeitschrift fur Naturforschung Section B, 2024. 79(2-3): p. 89-97. ISI[001161680700001].
[WOS]. HIV_02_2024.

4. Antiviral Activity of Lipophilic Nucleoside Tetraphosphate Compounds. Jia, X., D. Schols, and C. Meier. Journal of Medicinal Chemistry, 2024. 67(4): p. 2864-2883. PMID[38345794]. PMCID[PMC10895676].
[PubMed]. HIV_02_2024.

5. HIV-1 Transcription Inhibition Using Small RNA-binding Molecules. Khatkar, P., G. Mensah, S.B. Ning, M. Cowen, Y. Kim, A. Williams, F.A. Abulwerdi, Y.J. Zhao, C. Zeng, S.F.J. Le Grice, F. Kashanchi, S. Resino, and D. Sepulveda-Crespo. Pharmaceuticals, 2024. 17(1): 33. PMID[38256867]. PMCID[PMC10819208].
[PubMed]. HIV_02_2024.

6. Advances in Structure-Activity Relationships of HDAC Inhibitors as HIV Latency-reversing Agents. Khatun, S., S.A. Amin, D. Choudhury, B. Chowdhury, T. Jha, and S. Gayen. Expert Opinion on Drug Discovery, 2024. 19(3): p. 353-368. PMID[38258439].
[PubMed]. HIV_02_2024.

7. TGF-β Blockade Drives a Transitional Effector Phenotype in T Cells Reversing SIV Latency and Decreasing SIV Reservoirs in Vivo. Kim, J., D. Bose, M. Araínga, M.R. Haque, C.M. Fennessey, R.A. Caddell, Y. Thomas, D.E. Ferrell, S. Ali, E. Grody, Y. Goyal, C. Cicala, J. Arthos, B.F. Keele, M. Vaccari, R. Lorenzo-Redondo, T.J. Hope, F. Villinger, and E. Martinelli. Nature Communications, 2024. 15(1): 1348. PMID[38355731]. PMCID[PMC10867093].
[PubMed]. HIV_02_2024.

8. Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein. Liang, J.H., L.L. Zhai, Z.X. Liang, X.L. Chen, Y.S. Jiang, Y.L. Lin, S.Y. Feng, Y.X. Liu, W. Zhao, F.X. Wang, and R.A. Tripp. Vaccines, 2024. 12(1): 19. PMID[38250832]. PMCID[PMC10819093].
[PubMed]. HIV_02_2024.

9. N-Substituted Bicyclic Carbamoyl pyridones: Integrase Strand Transfer Inhibitors That Potently Inhibit Drug-resistant HIV-1 Integrase Mutants. Mahajan, P.S., S.J. Smith, M. Li, R. Craigie, S.H. Hughes, X.Z. Zhao, and T.R. Burke, Jr. ACS Infectious Diseases, 2024. 10(3): p. 917-927. PMID[38346249].
[PubMed]. HIV_02_2024.

10. Rational Design, Synthesis and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing 2-Phenylacetamide Derivatives as P2 Ligands with Potent Activity against DRV-resistant HIV-1 Variants. Meng, S., Y. Gao, G. Qiang, Z. Hu, Q. Shan, J. Wang, Y. Wang, and J. Mou. Bioorganic & Medicinal Chemistry Letters, 2024. 101: 129651. PMID[38342391].
[PubMed]. HIV_02_2024.

11. Naphthalene diimide-tetraazacycloalkane Conjugates are G-Quadruplex-based HIV-1 Inhibitors with a Dual Mode of Action. Nadai, M., F. Doria, I. Frasson, R. Perrone, V. Pirota, G. Bergamaschi, M. Freccero, and S.N. Richter. ACS Infectious Diseases, 2024. 10(2): p. 489-499. PMID[38175706]. PMCID[PMC10862543].
[PubMed]. HIV_02_2024.

12. Design, Synthesis, Docking Studies, and Biological Evaluation of Novel 2-Hydroxyacetophenone Derivatives as anti-HIV-1 Agents. Oliaie, S.S., M. Safakish, R.V. Roudsari, M. Mahboubi-Rabbani, Z. Hajimahdi, and A. Zarghi. Current HIV Research, 2023. 21(5): p. 290-300. PMID[37990893].
[PubMed]. HIV_02_2024.

13. Antiviral Potency of Long-acting Islatravir Subdermal Implant in SHIV-infected Macaques. Pons-Faudoa, F.P., N. Di Trani, S. Capuani, I. Facchi, A.M. Wood, B. Nehete, A. DeLise, S. Sharma, K.A. Shelton, L.R. Bushman, C.Y.X. Chua, M.M. Ittmann, J.T. Kimata, P.L. Anderson, P.N. Nehete, R.C. Arduino, and A. Grattoni. Journal of Controlled Release, 2024. 366: p. 18-27. PMID[38142963]. PMCID[PMC10922355].
[PubMed]. HIV_02_2024.

14. Inactivation of Cell-free HIV-1 by Designing Potent Peptides Based on Mutations in the CD4 Binding Site. Sabzian-Molaei, F., M.A. Ahmadi, Z. Nikfarjam, and M. Sabzian-Molaei. Medical and Biological Engineering and Computing, 2024. 62(2): p. 423-436. PMID[37889430].
[PubMed]. HIV_02_2024.

15. Synthesis and Lens Epithelium-derived Growth Factor- Dependent Human Immunodeficiency Virus Type-1 Integrase Inhibition Activity of Some 3-Acetyl-2H-1-derivatives. Srivastav, V.K., F. Esposito, E. Tramontano, and M. Tiwar. Indian Journal of Pharmaceutical Sciences, 2023. 85(5): p. 1329-1343. ISI[001104167300002].
[WOS]. HIV_02_2024.

16. Advanced Molecular Mechanisms of Modified DRV Compounds in Targeting HIV-1 Protease Mutations and Interrupting Monomer Dimerization. Tang, B., S. Luo, Q. Wang, P. Gao, and L. Duan. Physical Chemistry Chemical Physics, 2024. 26(6): p. 4989-5001. PMID[38258432].
[PubMed]. HIV_02_2024.

17. Functional Expression of Escherichia coli-derived Recombinant Plastocyanin from Canna indica L. and Its anti-HIV-1 Activities. Thepouyporn, A., W. Woradulayapinij, C. Napaswad, O. Reamtong, P. Kanchanadumkerng, and C. Wiwat. ScienceAsia, 2023. 49(6): p. 910-917. ISI[001137364700001].
[WOS]. HIV_02_2024.

18. A Truncated HIV Tat Demonstrates Potent and Specific Latency Reversal Activity. Van Gulck, E., M. Pardons, E. Nijs, N. Verheyen, K. Dockx, C. van den Eynde, E. Battivelli, J. Vega, E. Florence, B. Autran, N.M. Archin, D.M. Margolis, C. Katlama, C. Hamimi, I. Van den Wyngaert, F. Eyassu, L. Vandekerckhove, and D. Boden. Antimicrobial Agents and Chemotherapy, 2023. 67(11): e0041723. PMID[37874295]. PMCID[PMC10649039].
[PubMed]. HIV_02_2024.

Patent Citations

This month, no relevant HIV patents were identified.